18 Oct Oral Semaglutide As Effective As Injectable In Reducing A1C and Weight Loss

MedicalResearch.com Interview with:

Prof. Davies

Melanie J Davies CBE MB ChB MD FRCP FRCGP
Professor of Diabetes Medicine
NIHR Senior Investigator Emeritus
Diabetes Research Centre
Leicester Diabetes Centre – Bloom
University of Leicester

MedicalResearch.com: What is the background for this study? What are the main findings?

Response:  This was the first study to test the effectiveness of an oral GLP-1 in patients with type 2 diabetes.

The main findings were that compared to both placebo and a GLP-1, Semaglutide, delivered by sub-cutaneous injection weekly, the oral therapy delivered once a day produced better results than placebo and similar results to injectable GLP-1 with regard to reductions in HbA1c and weight loss.

MedicalResearch.com: What should clinicians and patients take away from your report?

Response: Readers should take away that this study provides good evidence that delivering GLP-1 therapy orally rather than by injectable therapy may be realized.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: At this stage two studies supported the company Novo Nordisk exploring further the potential for oral Semaglutide with a series of phase 3 studies which are now underway/ 

Disclosures: Professor Melanie Davies has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen, an advisory board member for Servier and as a speaker for Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceuticals International Inc. 

She has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim and Janssen.

 MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Davies M, Pieber TR, Hartoft-Nielsen M, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 DiabetesA Randomized Clinical Trial. JAMA. 2017;318(15):1460–1470. doi:10.1001/jama.2017.14752

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions. 

[wysija_form id=”1″]

Last Updated on October 18, 2017 by Marie Benz MD FAAD